Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20<sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma - Concepedia

Concepedia

Publication | Open Access

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20<sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

DOI Full Paper Access

269

Citations

29

References

2012

Year

Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nöel Milpied, John Radford, Nicolas Ketterer,

Journal of Clinical Oncology

Abstract

In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

References

	Year	Citations

Page 1